What do systematic reviews say?

aprepitant + palonosetron · adult cancer patients at risk for CINV caused by highly emetogenic chemotherapy

aprepitant + palonosetron · adult cancer patients at risk for CINV caused by highly emetogenic chemotherapy

aprepitant + ramosetron · adult cancer patients at risk for CINV caused by highly emetogenic chemotherapy

fosaprepitant + palonosetron · adult cancer patients at risk for CINV caused by highly emetogenic chemotherapy

fosaprepitant + granisetron · adult cancer patients at risk for CINV caused by highly emetogenic chemotherapy

aprepitant + ondansetron · adult cancer patients at risk for CINV caused by highly emetogenic chemotherapy

fosaprepitant + ondansetron · adult cancer patients at risk for CINV caused by highly emetogenic chemotherapy

At least 50% reduction in pain · adults with fibromyalgia

Adverse events as N of participants with at least one adverse event objective · adults with fibromyalgia enrolled in EERW studies

Serious adverse events · adults with fibromyalgia enrolled in EERW studies

Death · adults with fibromyalgia enrolled in EERW studies

PGIC very much improved · adults with fibromyalgia

At least 30% reduction in pain · adults with fibromyalgia

Moderate benefit · adults with fibromyalgia

Lack of efficacy withdrawal · adults with fibromyalgia

Withdrawals due to adverse events · adults with fibromyalgia

Serious adverse events · adults with fibromyalgia

Death · adults with fibromyalgia

Maintenance of initial therapeutic response of at least 30% pain intensity reduction over baseline and continued treatment at 13 or 26 weeks (equivalent to 'moderate benefit') · adults with fibromyalgia enrolled in EERW studies

Participant‐reported pain relief of 30% or greater · adults with moderate or severe pain associated with postherpetic neuralgia